Meldonium Effects. Successfully completed clinical study Mildronate

JSC «Grindeks» informs that the company has successfully completed a clinical study on the effect of the original product Mildronate tolerance of exercise in patients with angina.

International clinical study conducted company "Grindeks" in collaboration with scientists with a wealth of experience, scientific advisors and foreign contract organizations in accordance with 'good clinical practice »(ICH / GCP) and the requirements of the regulations of the European Union on I - IV phases of clinical trials.

A randomized, multinational, multicenter, double-blind, placebo-controlled study was conducted in 37 Mildronate research centers in Latvia, Lithuania, Russia and Ukraine. During his studied Mildronate therapeutic effect on the treatment of angina. The total volume of «Grindeks» investments in research totaled $ 1.6 mln.

Director of Research and Development of JSC «Grindeks» Nilss Poritis: "Patient selection, collecting all data and documentation were conducted in accordance with the requirements of the study protocol and the international standards of" good clinical practice ". Progress in research centers are strictly controlled, and its quality was checked and it was repeatedly confirmed by the results of the audit, which took place in research centers and in the company of «Grindeks» ".
Director of the Institute of Organic Synthesis, inventor Mildronate, scientific consultant clinical trials Ivars Kalvins: "As the inventor of the drug, I have always been convinced of the therapeutic efficacy of Mildronate® that confirmed and clinical practice, and research for many years. The results of the just concluded an international clinical trial once more approve effectiveness and the high reliability Mildronate® in the treatment of angina in combination with standard therapy. "

Chairman of the Board of JSC "Grindeks" Janis Romanovskis "Mildronate medication is the main enterprise. I want to stress the importance of this product for Latvia - Mildronate repeatedly recognized as the most great Latvian product. Its efficacy in the treatment of heart disease and highly appreciated in professional circles - among physicians and pharmacists, and among patients in 14 countries. The results will contribute to sales and registration Mildronate medication to new markets. "

Chairman of the Board of JSC «Grindeks» Kirov Lipman: "Every year the Company invests sighted about 10% of the total turnover in research and development. This investment, which is impossible without the further growth of the pharmaceutical companies. Investments in research Mildronate unsuccessful. Positive results of clinical studies will support that "Grindeks" was able to take the next step - how Mildronate next generation to enter as soon as possible. "

According to the practice of clinical trials are now under development is the publication of the results of clinical trials Mildronate. The research results will be widely discussed in the scientific and medical community at various conferences and symposia.

Angina is one of the most common heart disease. For angina is characterized by a number of symptoms: heaviness and pain in the chest, tightness of breath, choking, insufficient oxygen supply of the heart. Often angina patient provokes a physical load. If you do not take measures for the prevention and treatment of angina pectoris attacks may occur more frequently, the symptoms become worse. Angina indicates serious problems with heart health and significantly affects quality of life.

About JSC "Grindeks"
JSC «Grindeks» is the leading pharmaceutical company in the Baltic States. The main activities are research, development, manufacture and sale of original products, generics and active pharmaceutical ingredients. «Grindeks» specializes in the heart and cardiovascular system, antineoplastic drugs and medications that affect the central nervous system.

The Group of «Grindeks» consists of four subsidiary companies in Latvia, Estonia and Russia; representatives and representative offices in 14 countries. The company's products are exported to over 40 countries and 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as in Japan and America. The shares of JSC «Grindeks» shares are listed in the Official List «NASDAQ OMX Riga».